Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Cleveland |
| State: |
|
Ohio |
| Zip Code: |
|
44195 |
| Conditions: |
|
Ciliary Body and Choroid Melanoma, Medium/Large Size - Ciliary Body and Choroid Melanoma, Small Size - Iris Melanoma - Recurrent Intraocular Melanoma |
| Purpose: |
|
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving
interferon alfa-2b together with dacarbazine may be an effective treatment for primary uveal
melanoma.
PURPOSE: This phase II trial is studying how well giving dacarbazine together with
recombinant interferon alfa-2b works in treating patients with primary uveal melanoma with
genetic imbalance.
|
| Study Summary: |
|
PRIMARY OBJECTIVES:
I. Assess disease-free survival (DFS) with sequential dacarbazine and interferon-alfa-2b as
an adjuvant to primary therapy for patients with uveal melanoma with genetic imbalance.
SECONDARY OBJECTIVES:
I. Evaluate side effects and assess safety in the patient population.
II. Examine the relationship between the levels of plasma biomarkers of immune function and
tumor invasion and the clinical outcome.
OUTLINE: Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the
second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3
times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 6 months.
|
| Criteria: |
|
Inclusion
- Patients must have a diagnosis, either cytologic or histologic, of melanoma of the
iris, ciliary body and/or choroid
- Patient's tumor must exhibit monosomy 3 and/or 8q amplification as determined by
karyotype, CGH, PCR-based microsatellite, and/or FISH analysis; tissue or cells for
analysis can be obtained at enucleation, resection, or by FNA
- Patients must have undergone adequate primary therapy; this can include enucleation,
brachytherapy, proton beam radiotherapy, stereotactic irradiation, trans-scleral
local resection, transretinal resection or diode laser thermotherapy
- Patients must have had chest X-ray and hepatic ultrasound or other imaging methods
such as CT or MRI to eliminate distant disease
- Patients must have a performance status (ECOG) of < 2
- Patients must be entered within 56 days of completing primary therapy
- WBC >= 3.0 x 10^9/L
- Neutrophils >= 1.5 x 10^9/L
- Platelets >= 100 x 10^9/L
- INR and PTT < 1.5 x upper limit of normal
- Hemoglobin >= 10 gm/100 ml
- Creatinine =< 2 mg/dl
- Bilirubin (total) =< 1.5 mg/dl
- ALT =< 1.5 x upper limit of normal
- Alkaline phosphatase =< 1.5 x upper limit of normal
- AST =< 1.5 x upper limit of normal
- Patients must not have received any other systemic therapy for melanoma
- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control) prior to study entry and for the
duration of study participation; should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately
- All patients must be informed of the investigational nature of this study and must
provide written informed consent in accordance with institutional and federal
guidelines; a copy of the informed consent document signed by the patient must be
given to the patient
Exclusion
- Patients with metastasis
- Patients that are pregnant or breastfeeding
- Patients may not be receiving any other investigational agents
- Patients with a history of immunodeficiency or autoimmune diseases are not eligible;
patients requiring therapy with corticosteroids or other immunosuppressives are not
eligible; patients requiring ongoing replacement therapy with physiologic doses of
corticosteroids will be eligible.
- Patients with uncontrolled intercurrent illness including, but not limited to ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements are not eligible
- Patients who are known to be positive for HIV or HepBAg
- No patient may have had a malignancy other than a malignant melanoma, with the
following exceptions: basal or squamous cell carcinomas of the skin; carcinoma
in-situ of the uterine cervix; any malignancy treated with curative intent and in
complete remission for > 3 years
- Patients with organ allografts
|
| NCT ID: |
|
NCT01100528 |
| Primary Contact: |
|
Principal Investigator
Pierre Triozzi
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Cleveland, Ohio 44195
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|